Now showing items 1-3 of 3
Pharmacovigilance in hospice/palliative care: rapid report of net clinical effect of metoclopramide
((C) Mary Ann Liebert, Inc., 2012-07-20)
Background: Understanding the performance of prescribed medications in day-to-day practice is important to minimize harm, maximize clinical benefits, and, eventually, better target the people who are most likely to benefit, ...
End-of-life research: do we need to build proxy consent into all clinical trial protocols studying the terminal phase?
(Mary Ann Liebert, Inc., 2012-09-04)
Research into symptoms that occur at the end of life is paramount for ensuring we provide the best possible care for patients in the terminal phase, yet obtaining informed consent from the study participant is not possible ...
An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice
(Mary Ann Liebert, Inc., 2012-02-21)
Background: Medication registration currently requires evidence of safety and efficacy from adequately powered phase 3 studies. Pharmacovigilance (phase 4 studies, postmarketing data, adverse drug reaction reporting) provide ...